Adjuvant PIKA protects hepatoma cells from dengue virus infection by promoting a TBK-1-dependent innate immune response

Archives of Virology

Volumn 158, Issue 4, 2013, Pages 829-838

  Zhang, Ping ^a,b   Wu, Siyu ^a,b   Li, Lietao ^c   Liang, Zhaoduan ^a,b   Li, Yuye ^a,b   Feng, Lianqiang ^a,b   Huang, Xi ^a,b  

^a SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c Yisheng Biopharma (S) Pte Ltd   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

DENGUE VIRUS;

EID: 84876059066     PISSN: 03048608     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00705-012-1556-8     Document Type: Article

References (29)

1. Halstead SB (2007) Dengue. Lancet 370(9599): 1644-1652. doi: 10. 1016/S0140-6736(07)61687-0.
2. Simmons CP, Farrar JJ, Nguyen V, Wills B (2012) Dengue. N Engl J Med 366(15): 1423-1432. doi: 10. 1056/NEJMra1110265.
3. Gubler DJ (1998) Dengue and dengue hemorrhagic fever. Clin Microbiol Rev 11(3): 480-496.
4. Haller O, Kochs G, Weber F (2006) The interferon response circuit: induction and suppression by pathogenic viruses. Virology 344(1): 119-130.
5. Diamond MS, Roberts TG, Edgil D, Lu B, Ernst J, Harris E (2000) Modulation of dengue virus infection in human cells by alpha, beta, and gamma interferons. J Virol 74(11): 4957-4966.
6. Johnson AJ, Roehrig JT (1999) New mouse model for dengue virus vaccine testing. J Virol 73(1): 783-786.
7. Morrison J, Aguirre S, Fernandez-Sesma A (2012) Innate immunity evasion by dengue virus. Viruses 4(3): 397-413. doi: 10. 3390/v4030397.
8. Rodriguez-Madoz JR, Bernal-Rubio D, Kaminski D, Boyd K, Fernandez-Sesma A (2010) Dengue virus inhibits the production of type I interferon in primary human dendritic cells. J Virol 84(9): 4845-4850. doi: 10. 1128/JVI. 02514-09.
9. Matsumoto M, Seya T (2008) TLR3: interferon induction by double-stranded RNA including poly(I: C). Adv Drug Deliv Rev 60(7): 805-812. doi: 10. 1016/j. addr. 2007. 11. 005.
10. Robinson RA, DeVita VT, Levy HB, Baron S, Hubbard SP, Levine AS (1976) A phase I-II trial of multiple-dose polyriboinosic-polyribocytidylic acid in patieonts with leukemia or solid tumors. J Natl Cancer Inst 57(3): 599-602.
11. Wong JP, Yang H, Nagata L, Kende M, Levy H, Schnell G, Blasetti K (1999) Liposome-mediated immunotherapy against respiratory influenza virus infection using double-stranded RNA poly ICLC. Vaccine 17(13-14): 1788-1795.
12. Lau YF, Tang LH, McCall AW, Ooi EE, Subbarao K (2010) An adjuvant for the induction of potent, protective humoral responses to an H5N1 influenza virus vaccine with antigen-sparing effect in mice. J Virol 84(17): 8639-8649. doi: 10. 1128/JVI. 00596-10.
13. Lau YF, Tang LH, Ooi EE, Subbarao K (2010) Activation of the innate immune system provides broad-spectrum protection against influenza A viruses with pandemic potential in mice. Virology 406(1): 80-87. doi: 10. 1016/j. virol. 2010. 07. 008.
14. Lau YF, Tang LH, Ooi EE (2009) A TLR3 ligand that exhibits potent inhibition of influenza virus replication and has strong adjuvant activity has the potential for dual applications in an influenza pandemic. Vaccine 27(9): 1354-1364. doi: 10. 1016/j. vaccine. 2008. 12. 048.
15. Lin HX, Gontier C, Saron MF, Perrin P (1993) A new immunostimulatory complex (PICKCa) in experimental rabies: antiviral and adjuvant effects. Arch Virol 131(3-4): 307-319.
16. Shen E, Li L, Feng L, Lu L, Yao Z, Lin H, Wu C (2007) PIKA as an adjuvant enhances specific humoral and cellular immune responses following the vaccination of mice with HBsAg plus PIKA. Cell Mol Immunol 4(2): 113-120.
17. Liang Z, Wu S, Li Y, He L, Wu M, Jiang L, Feng L, Zhang P, Huang X (2011) Activation of Toll-like receptor 3 impairs the dengue virus serotype 2 replication through induction of IFN-beta in cultured hepatoma cells. PLoS One 6(8): e23346. doi: 10. 1371/journal. pone. 0023346.
18. Reed LJ, Muench H (1938) A simple method of estimating fifty percent endpoints. Am J Hyg 27: 493-497.
19. O'Reilly DR, Miller LK, Luckow VA (1994) Baculovirus expression vectors: a laboratory manual. Oxford University Press, Oxford.
20. Maul A (1991) Aspects statistiques des me′thodes de quantification en virologie. In: Lavoisier (ed) Virologie des milieux hydriques Schwartzbrod Tec & Doc, Paris, pp 143-171.
21. Pfaffl MW (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29(9): e45.
22. Ramakers C, Ruijter JM, Deprez RH, Moorman AF (2003) Assumption-free analysis of quantitative real-time polymerase chain reaction (PCR) data. Neurosci Lett 339(1): 62-66. doi: S0304394002014234.
23. Schefe JH, Lehmann KE, Buschmann IR, Unger T, Funke-Kaiser H (2006) Quantitative real-time RT-PCR data analysis: current concepts and the novel "gene expression's CT difference" formula. J Mol Med (Berl) 84(11): 901-910. doi: 10. 1007/s00109-006-0097-6.
24. Wu MH, Zhang P, Huang X (2010) Toll-like receptors in innate immunity and infectious diseases. Front Med China 4(4): 385-393.
25. Samuel CE (2001) Antiviral actions of interferons. Clin Microbiol Rev 14(4): 778-809 Table of contents.
26. Lin RJ, Yu HP, Chang BL, Tang WC, Liao CL, Lin YL (2009) Distinct antiviral roles for human 2', 5'-oligoadenylate synthetase family members against dengue virus infection. J Immunol 183(12): 8035-8043.
27. Toth AM, Zhang P, Das S, George CX, Samuel CE (2006) Interferon action and the double-stranded RNA-dependent enzymes ADAR1 adenosine deaminase and PKR protein kinase. Prog Nucleic Acid Res Mol Biol 81: 369-434.
28. Haller O, Staeheli P, Kochs G (2007) Interferon-induced Mx proteins in antiviral host defense. Biochimie 89(6-7): 812-818. doi: 10. 1016/j. biochi. 2007. 04. 015.
29. Borden EC, Sen GC, Uze G, Silverman RH, Ransohoff RM, Foster GR, Stark GR (2007) Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov 6(12): 975-990.